Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Postmenopausal hormone therapy, timing of initiation, APOE and cognitive decline.

Kang JH, Grodstein F.

Neurobiol Aging. 2012 Jul;33(7):1129-37. doi: 10.1016/j.neurobiolaging.2010.10.007. Epub 2010 Nov 30.

2.

Postmenopausal hormone therapy and risk of cognitive decline in community-dwelling aging women.

Kang JH, Weuve J, Grodstein F.

Neurology. 2004 Jul 13;63(1):101-7.

PMID:
15249618
3.

Accelerated cell aging in female APOE-ε4 carriers: implications for hormone therapy use.

Jacobs EG, Kroenke C, Lin J, Epel ES, Kenna HA, Blackburn EH, Rasgon NL.

PLoS One. 2013;8(2):e54713. doi: 10.1371/journal.pone.0054713. Epub 2013 Feb 13.

4.

APOE E4 status predicts age-related cognitive decline in the ninth decade: longitudinal follow-up of the Lothian Birth Cohort 1921.

Schiepers OJ, Harris SE, Gow AJ, Pattie A, Brett CE, Starr JM, Deary IJ.

Mol Psychiatry. 2012 Mar;17(3):315-24. doi: 10.1038/mp.2010.137. Epub 2011 Jan 25.

PMID:
21263443
5.

Postmenopausal hormone therapy and cognitive function in healthy older women.

Grodstein F, Chen J, Pollen DA, Albert MS, Wilson RS, Folstein MF, Evans DA, Stampfer MJ.

J Am Geriatr Soc. 2000 Jul;48(7):746-52.

PMID:
10894312
6.

Postmenopausal estrogen and estrogen-progestin use and 2-year rate of cognitive change in a cohort of older Japanese American women: The Kame Project.

Rice MM, Graves AB, McCurry SM, Gibbons LE, Bowen JD, McCormick WC, Larson EB.

Arch Intern Med. 2000 Jun 12;160(11):1641-9.

PMID:
10847257
7.

Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.

Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D; WHIMS Investigators.

JAMA. 2003 May 28;289(20):2663-72.

PMID:
12771113
8.

Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study.

MacLennan AH, Henderson VW, Paine BJ, Mathias J, Ramsay EN, Ryan P, Stocks NP, Taylor AW.

Menopause. 2006 Jan-Feb;13(1):28-36.

PMID:
16607096
9.

Subjective cognitive concerns, episodic memory, and the APOE ε4 allele.

Samieri C, Proust-Lima C, M Glymour M, Okereke OI, Amariglio RE, Sperling RA, Rentz DM, Grodstein F.

Alzheimers Dement. 2014 Nov;10(6):752-759.e1. doi: 10.1016/j.jalz.2014.06.012. Epub 2014 Sep 23.

10.

Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study.

Knopman DS, Mosley TH, Catellier DJ, Coker LH; Atherosclerosis Risk in Communities Study Brain MRI Study.

Alzheimers Dement. 2009 May;5(3):207-14. doi: 10.1016/j.jalz.2009.01.027. Epub 2009 Apr 11.

PMID:
19362884
11.

Association between apolipoprotein E ε4 and longitudinal cognitive decline: nested case-control study among chinese community-dwelling elders.

Ma F, Wang J, Miao R, Zhao W, Wang Q.

Neuropsychobiology. 2011;64(2):102-9. doi: 10.1159/000324991. Epub 2011 Jun 21.

PMID:
21701228
12.

Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction.

Yaffe K, Haan M, Byers A, Tangen C, Kuller L.

Neurology. 2000 May 23;54(10):1949-54.

PMID:
10822435
13.

Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment.

Caselli RJ, Reiman EM, Locke DE, Hutton ML, Hentz JG, Hoffman-Snyder C, Woodruff BK, Alexander GE, Osborne D.

Arch Neurol. 2007 Sep;64(9):1306-11.

PMID:
17846270
14.

Apolipoprotein E ε4 and later-life decline in cognitive function and grip strength.

Batterham PJ, Bunce D, Cherbuin N, Christensen H.

Am J Geriatr Psychiatry. 2013 Oct;21(10):1010-9. doi: 10.1016/j.jagp.2013.01.035. Epub 2013 Feb 6.

PMID:
23567378
15.

Cognitive functions, apolipoprotein E genotype and hormonal replacement therapy of postmenopausal women.

Bojar I, Gujski M, Raczkiewicz D, Rothenberg KG.

Neuro Endocrinol Lett. 2013;34(7):635-42.

PMID:
24464001
16.

Apolipoprotein E, cardiovascular disease and cognitive function in aging women.

Kang JH, Logroscino G, De Vivo I, Hunter D, Grodstein F.

Neurobiol Aging. 2005 Apr;26(4):475-84.

PMID:
15653176
17.

Characteristics of hormone therapy, cognitive function, and dementia: the prospective 3C Study.

Ryan J, Carrière I, Scali J, Dartigues JF, Tzourio C, Poncet M, Ritchie K, Ancelin ML.

Neurology. 2009 Nov 24;73(21):1729-37. doi: 10.1212/WNL.0b013e3181c34b0c.

18.

C-reactive protein, APOE genotype and longitudinal cognitive change in an older population.

Lima TA, Adler AL, Minett T, Matthews FE, Brayne C, Marioni RE; Medical Research Council Cognitive Function and Ageing Study.

Age Ageing. 2014 Mar;43(2):289-92. doi: 10.1093/ageing/aft193. Epub 2013 Dec 3.

19.

Gene-behavior interaction of depressive symptoms and the apolipoprotein E {varepsilon}4 allele on cognitive decline.

Rajan KB, Wilson RS, Skarupski KA, Mendes de Leon CF, Evans DA.

Psychosom Med. 2014 Feb;76(2):101-8. doi: 10.1097/PSY.0000000000000029. Epub 2014 Jan 16.

20.

APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.

Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Hurtig HI, Van Deerlin VM, Ritz B, Rausch R, Rhodes SL, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson AL, Espay AJ, Revilla FJ, Devoto J, Hu SC, Cholerton BA, Wan JY, Montine TJ, Edwards KL, Zabetian CP.

JAMA Neurol. 2014 Nov;71(11):1405-12. doi: 10.1001/jamaneurol.2014.1455.

Supplemental Content

Support Center